X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA NOVARTIS PLETHICO PHARMA/
NOVARTIS
 
P/E (TTM) x -1.1 361.2 - View Chart
P/BV x 0.0 17.8 0.1% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 PLETHICO PHARMA   NOVARTIS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
NOVARTIS
Mar-16
PLETHICO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs395982 40.2%   
Low Rs31556 5.6%   
Sales per share (Unadj.) Rs604.4252.9 239.0%  
Earnings per share (Unadj.) Rs32.562.1 52.3%  
Cash flow per share (Unadj.) Rs51.363.3 81.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs473.6363.6 130.2%  
Shares outstanding (eoy) m34.0831.96 106.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.0 11.6%   
Avg P/E ratio x6.612.4 53.0%  
P/CF ratio (eoy) x4.212.2 34.2%  
Price / Book Value ratio x0.52.1 21.3%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m7,26224,580 29.5%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,5961,801 88.6%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m20,5988,083 254.8%  
Other income Rs m386829 46.6%   
Total revenues Rs m20,9848,913 235.4%   
Gross profit Rs m2,818234 1,203.1%  
Depreciation Rs m64237 1,750.1%   
Interest Rs m1,5932 88,511.1%   
Profit before tax Rs m9691,025 94.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m-138752 -18.4%   
Profit after tax Rs m1,1071,986 55.7%  
Gross profit margin %13.72.9 472.1%  
Effective tax rate %-14.373.4 -19.5%   
Net profit margin %5.424.6 21.9%  
BALANCE SHEET DATA
Current assets Rs m18,87712,678 148.9%   
Current liabilities Rs m11,8962,433 489.0%   
Net working cap to sales %33.9126.7 26.7%  
Current ratio x1.65.2 30.5%  
Inventory Days Days3633 109.9%  
Debtors Days Days19822 879.7%  
Net fixed assets Rs m9,86169 14,249.3%   
Share capital Rs m341160 213.2%   
"Free" reserves Rs m12,33111,460 107.6%   
Net worth Rs m16,13911,621 138.9%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14614,400 230.2%  
Interest coverage x1.6570.5 0.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.6 110.7%   
Return on assets %8.113.8 59.0%  
Return on equity %6.917.1 40.1%  
Return on capital %12.323.6 52.1%  
Exports to sales %21.40.7 2,869.8%   
Imports to sales %15.218.6 81.9%   
Exports (fob) Rs m4,40260 7,313.0%   
Imports (cif) Rs m3,1361,503 208.7%   
Fx inflow Rs m4,402186 2,363.1%   
Fx outflow Rs m3,1841,821 174.9%   
Net fx Rs m1,219-1,635 -74.5%   
CASH FLOW
From Operations Rs m2,4372,531 96.3%  
From Investments Rs m-6,265-8,270 75.8%  
From Financial Activity Rs m2,490-386 -645.6%  
Net Cashflow Rs m-1,337-6,125 21.8%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.3 2.0 215.0%  
FIIs % 5.5 1.6 343.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 21.5 34.9%  
Shareholders   10,665 41,647 25.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  AJANTA PHARMA  UNICHEM LAB  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - SUVEN LIFE COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS